Ignite Creation Date:
2025-12-24 @ 11:21 PM
Ignite Modification Date:
2025-12-31 @ 9:20 AM
Study NCT ID:
NCT05206656
Status:
COMPLETED
Last Update Posted:
2022-11-23
First Post:
2021-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Sponsor:
Hunan Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-09
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2021-12-16
First Submit QC Date:
None
Study First Post Date:
2022-01-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-21
Last Update Post Date:
2022-11-23
Last Update Post Date Type:
ACTUAL